Segall Bryant & Hamill’s TG Therapeutics TGTX Stock Holding History

Segall Bryant & Hamill’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.07M	Sell	128,597 -55,600	-30%	-$2.28M	0.08%	281
2026 Q1	$6.12M	Sell	184,197 -8,257	-4%	-$246K	0.09%	282
2025 Q4	$5.74M	Buy	192,454 +114,621	+147%	+$3.74M	0.08%	299
2025 Q3	$2.81M	Sell	77,833 -437	-0.6%	-$14.4K	0.04%	377
2025 Q2	$2.82M	Sell	78,270 -7,201	-8%	-$268K	0.04%	382
2025 Q1	$3.37M	Buy	85,471 +5,953	+7%	+$200K	0.05%	363
2024 Q4	$2.39M	Buy	79,518 +27,128	+52%	+$779K	0.03%	412
2024 Q3	$1.23M	Buy	+52,390	New	+$1.14M	0.02%	492
2021 Q2	–	Sell	-5,000	Closed	-$241K	–	823
2021 Q1	$241K	Hold	5,000	–	–	﹤0.01%	763
2020 Q4	$260K	Buy	+5,000	New	+$169K	﹤0.01%	675
2018 Q1	–	Sell	-61,092	Closed	-$501K	–	622
2017 Q4	$501K	Buy	61,092 +7,500	+14%	+$65.5K	0.01%	420
2017 Q3	$635K	Hold	53,592	–	–	0.01%	398
2017 Q2	$539K	Buy	53,592 +8,092	+18%	+$90.6K	0.01%	419
2017 Q1	$530K	Buy	45,500 +30,000	+194%	+$215K	0.01%	404
2016 Q4	$72K	Buy	+15,500	New	+$90.9K	﹤0.01%	533

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Segall Bryant & Hamill's TGTX Position: Q2 2026 in Review

Segall Bryant & Hamill reduced its TG Therapeutics (TGTX) stake by 30% in Q2 2026, selling an estimated $2.28M and leaving 128,597 shares worth $7.07M. The position accounts for 0.08% of the portfolio, ranked #281.

Segall Bryant & Hamill first reported a position in TGTX in Q4 2016 and has held it in 15 quarters since. 427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Segall Bryant & Hamill held 128,597 shares of TG Therapeutics worth $7.07M as of Q2 2026.
Segall Bryant & Hamill sold 55,600 TG Therapeutics shares in Q2 2026, an estimated $2.28M.
TG Therapeutics made up 0.08% of Segall Bryant & Hamill's portfolio in Q2 2026, its #281 holding.
Segall Bryant & Hamill first reported a position in TG Therapeutics in Q4 2016 and has held it in 15 quarters since.
427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Segall Bryant & Hamill's 13F filing for Q2 2026, filed 12 Aug 2026.